Dipartimento di Scienze Biomediche, Università degli Studi di Sassari, Sassari, Italy; IRGB-CNR, Istituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche (CNR), Monserrato, Cagliari, Italy.
IRGB-CNR, Istituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche (CNR), Monserrato, Cagliari, Italy.
Trends Genet. 2018 Jul;34(7):558-570. doi: 10.1016/j.tig.2018.04.004. Epub 2018 May 23.
Choosing the right biological target is the critical primary decision for the development of new drugs. Systematic genetic association testing of both human diseases and quantitative traits, along with resultant findings of coincident associations between them, is becoming a powerful approach to infer drug targetable candidates and generate in vitro tests to identify compounds that can modulate them therapeutically. Here, we discuss opportunities and challenges, and infer criteria for the optimal use of genetic findings in the drug discovery pipeline.
选择正确的生物靶标是开发新药的关键首要决策。对人类疾病和数量性状进行系统的遗传关联测试,以及随之发现它们之间存在一致的关联,正成为一种推断药物靶标候选物并产生体外测试以鉴定可调节它们的化合物的强大方法。在这里,我们讨论了机会和挑战,并推断了在药物发现管道中最佳利用遗传发现的标准。